Scientists at Sanford Burnham Prebys Medical Discovery Institute and Loma Linda University Health have demonstrated the promise of applying magnetic resonance imaging (MRI) to predict the efficacy of using human neural stem cells to treat a brain injury—a first-ever “biomarker” for regenerative medicine that could help personalize stem cell treatments for neurological disorders and improve efficacy. The study was published in Cell Reports.
The California Institute for Regenerative Medicine (CIRM) has awarded a $4.96 million grant to Sanford Burnham Prebys Professor Evan Y. Snyder, M.D., Ph.D. The funding will allow Snyder to complete pre-investigational new drug (IND)-enabling studies, a step toward securing U.S. Food & Drug Administration (FDA) approval of a human trial for neural stem cells as a potential treatment for newborns who experience oxygen and blood-flow deprivation during birth. Called perinatal hypoxic-ischemic brain injury (HII), the lack of oxygen and blood flow to the brain can cause cerebral palsy and other permanent neurological disorders.